Vor Biopharma (VOR) Competitors

Vor Biopharma logo
$1.37 +0.04 (+3.01%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$1.36 -0.01 (-0.73%)
As of 02/14/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VOR vs. TERN, TSHA, ATAI, ANNX, PHAT, ESPR, CMRX, ACB, TRML, and MBX

Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Terns Pharmaceuticals (TERN), Taysha Gene Therapies (TSHA), Atai Life Sciences (ATAI), Annexon (ANNX), Phathom Pharmaceuticals (PHAT), Esperion Therapeutics (ESPR), Chimerix (CMRX), Aurora Cannabis (ACB), Tourmaline Bio (TRML), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.

Vor Biopharma vs.

Terns Pharmaceuticals (NASDAQ:TERN) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Terns Pharmaceuticals has a beta of -0.34, indicating that its share price is 134% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of -0.45, indicating that its share price is 145% less volatile than the S&P 500.

Vor Biopharma's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Terns PharmaceuticalsN/A -32.76% -31.33%
Vor Biopharma N/A N/A N/A

Terns Pharmaceuticals currently has a consensus target price of $18.30, suggesting a potential upside of 350.74%. Vor Biopharma has a consensus target price of $11.36, suggesting a potential upside of 728.99%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Terns Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Vor Biopharma
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/A-$90.21M-$1.18-3.44
Vor BiopharmaN/AN/AN/A-$1.65-0.83

98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 15.1% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Vor Biopharma had 3 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 4 mentions for Vor Biopharma and 1 mentions for Terns Pharmaceuticals. Vor Biopharma's average media sentiment score of -0.25 beat Terns Pharmaceuticals' score of -0.55 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Terns Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
Vor Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Vor Biopharma received 10 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 69.33% of users gave Vor Biopharma an outperform vote while only 60.87% of users gave Terns Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Terns PharmaceuticalsOutperform Votes
42
60.87%
Underperform Votes
27
39.13%
Vor BiopharmaOutperform Votes
52
69.33%
Underperform Votes
23
30.67%

Summary

Vor Biopharma beats Terns Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VOR vs. The Competition

MetricVor Biopharma IndustryMedical SectorNYSE Exchange
Market Cap$94.08M$2.24B$5.76B$20.30B
Dividend YieldN/A13.99%5.27%3.68%
P/E Ratio-0.838.8326.2245.83
Price / SalesN/A2,477,991.13456.5716.48
Price / CashN/A15.2346.0620.33
Price / BookN/A3.107.355.73
Net IncomeN/A$66.46M$3.19B$1.00B
7 Day Performance-0.72%6.36%1.69%0.13%
1 Month Performance3.01%8.90%4.13%1.37%
1 Year Performance-33.50%10.24%22.24%16.03%

Vor Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VOR
Vor Biopharma
2.4718 of 5 stars
$1.37
+3.0%
$11.36
+729.0%
-33.5%$94.08MN/A-0.83140
TERN
Terns Pharmaceuticals
4.5472 of 5 stars
$4.49
+0.1%
$18.30
+308.0%
-48.3%$379.26MN/A-3.7840
TSHA
Taysha Gene Therapies
2.7131 of 5 stars
$1.86
+6.0%
$6.63
+257.1%
-14.7%$378.11M$15.45M2.93180
ATAI
Atai Life Sciences
2.6956 of 5 stars
$2.25
+3.3%
$9.00
+299.8%
+25.0%$373.19M$310,000.00-2.7580Analyst Revision
ANNX
Annexon
2.5049 of 5 stars
$3.46
+0.4%
$15.80
+357.3%
-40.2%$368.27MN/A-3.2960Short Interest ↑
News Coverage
PHAT
Phathom Pharmaceuticals
2.8183 of 5 stars
$5.38
-5.9%
$23.00
+327.9%
-37.9%$367.54M$680,000.00-0.94110Analyst Forecast
ESPR
Esperion Therapeutics
4.5779 of 5 stars
$1.86
-0.3%
$7.25
+290.8%
-30.9%$365.50M$295.45M-2.90200Short Interest ↓
Analyst Revision
CMRX
Chimerix
4.157 of 5 stars
$4.07
-3.4%
$8.50
+109.1%
+280.9%$364.26M$320,000.00-4.3190
ACB
Aurora Cannabis
0.6776 of 5 stars
$6.62
+9.7%
N/A+60.6%$359.11M$200.35M130.951,073
TRML
Tourmaline Bio
2.0902 of 5 stars
$13.80
-3.3%
$54.00
+291.2%
-67.6%$353.58MN/A-4.8944Short Interest ↑
Positive News
MBX
MBX Biosciences
1.7046 of 5 stars
$10.47
-15.2%
$37.25
+255.9%
N/A$343.16MN/A0.0036

Related Companies and Tools


This page (NYSE:VOR) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners